Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-hour FEV1 profile of olodaterol in COPD
NCT00846768Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2009
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of olodaterol in chronic obstructive pulmonary disease (COPD), sponsored by Boehringer Ingelheim. Started Feb 2009; status: completed.
02
Drugs
olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00846768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00846768.